VistaGen Therapeutics

Update in progress

VTGN (NasdaqCM)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Vistagen Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on therapies for neuropsychiatric and neurological disorders. Its intranasal pherine programs include Fasedienol (Phase III for social anxiety disorder) and Itruvone (Phase II for major depressive disorder), plus PH80, PH15, PH284 in Phase II for menopausal symptoms, cognitive impairment, and loss of appetite/cachexia, respectively; AV-101 is an oral NMDA receptor–targeting prodrug. Also licensed to AffaMed for fasedienol. Founded 1998, HQ in South San Francisco.

Company score

Sentiment: -0.36; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: -0.08; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: -0.28; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: -0.08; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: -0.22; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive